Our observations also provide a rationale for combining FGFR3 inhibitors with PD-1/PD-L1 inhibitors as a targeted therapeutic strategy to modulate the T-cell-depleted phenotype of UTUC. Here, FGFR3 is linked to renal pelvis/ureter urothelial carcinoma.